Recent news highlights strong revenue growth and operational updates for American Shared Hospital Services, including earnings calls and quarterly earnings reports.

• American Shared Hospital Services reported strong revenue growth as of March 31, 2026 [N1].
• The company held its Q1 2025 earnings conference call on May 15, 2025 [N2].
• AMS reported 17% year-over-year revenue growth for Q1 2025 and announced expansion plans [N3].
• Quarterly earnings results were reported on April 4, 2025 [N4].
• An earnings preview discussed recent insider trading and hedge fund activity as of March 25, 2025 [N5].

The company’s recent revenue growth, including a 17% year-over-year increase reported for Q1 2025, and expansion into new geographic markets and additional radiation therapy technologies suggest operational momentum. The dual-segment business model combining leasing and direct patient services diversifies revenue sources. Ongoing contract renewals and potential new equipment placements could support business stability. The company’s efforts to manage liquidity and extend credit facilities are critical to sustaining operations [N1][N3][S1].

AMS faces liquidity constraints with current liabilities exceeding current assets and a current ratio below 1, raising concerns about its ability to meet short-term obligations without asset sales or refinancing. The company’s credit facilities mature in April 2026, with no assurance of extension, posing refinancing risk. Customer concentration risk is high, with two customers accounting for over half of revenue, and loss of any major customer could materially impact results. The material weakness in internal controls over financial reporting may affect financial transparency and investor confidence [S1][S2].

AMS’s moat is based on its specialized niche in stereotactic radiosurgery and advanced radiation therapy equipment leasing and operation, including exclusive use of Gamma Knife systems and PBRT units. The high capital cost of equipment and the need for specialized medical centers with neurosurgery and radiation oncology departments create barriers to entry. Long-term contracts with hospitals and ownership of direct patient service facilities in select geographic locations provide recurring revenue streams. However, customer concentration and reliance on a single equipment manufacturer (Elekta) present vulnerabilities [S1].

• Liquidity Risk: Current liabilities exceed current assets with a current ratio of 0.77 as of June 30, 2026, indicating potential liquidity challenges. The company may need to sell assets, restructure debt, or raise equity under potentially onerous terms.
• Credit Facility Maturity: The $22 million credit agreement matures in April 2026. Discussions for extension are ongoing but uncertain, posing refinancing risk that could impact operations and liquidity.
• Customer Concentration: Two customers accounted for approximately 26% and 31% of revenue in 2025. Loss or reduced business from these customers could materially affect financial performance.
• Dependence on Equipment Supplier: All radiosurgery devices have been purchased from Elekta to date. Dependence on a single supplier may pose supply chain or pricing risks.
• Internal Control Weakness: A material weakness in internal control over financial reporting was identified as of December 31, 2025, which could affect timely and accurate financial disclosures and investor confidence.

• American Shared Hospital Services (AMS) provides turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services [S1].
• The company operates two reportable segments: medical equipment leasing and direct patient services [S1].
• The medical equipment leasing segment operates under fee-per-use or revenue sharing contracts, sharing revenue and operating costs with hospitals [S1].
• As of December 31, 2025, AMS leased seven Gamma Knife systems and one Proton Beam Radiation Therapy (PBRT) system [S1].
• AMS owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador, one single-unit radiation therapy facility in Puebla, Mexico, and a 60% interest in three single-unit radiation therapy facilities in Rhode Island acquired in May 2024 [S1].
• The company’s revenue drivers include number of sites, procedure volume, and reimbursement [S1].
• AMS’s revenue for the three months ended March 31, 2026 was $7.084 million, up from $6.112 million in the prior year period, with rental revenue from medical equipment leasing at $3.02 million and direct patient services revenue at $4.064 million [S2].
• Net loss attributable to AMS for the three months ended March 31, 2026 was $612,000, compared to $625,000 in the prior year period [S2].
• Basic and diluted loss per share for the three months ended March 31, 2026 was $0.09, compared to $0.10 in the prior year period [S2].
• As of June 30, 2026, AMS had cash and cash equivalents of $6.511 million and total current assets of $17.368 million [S2].
• Current liabilities as of June 30, 2026 were $22.424 million, with total liabilities of $26.684 million [S2].
• Shareholders’ equity as of June 30, 2026 was $23.111 million for AMS and $26.705 million including non-controlling interests [S2].
• Liquidity ratios as of June 30, 2026 included a current ratio of 0.77 and a cash ratio of 0.29, indicating current liabilities exceed current assets [S2].
• AMS’s long-term debt includes a $22 million credit agreement with Fifth Third Bank, with three loan facilities maturing April 9, 2026, carrying floating interest rates and secured by substantially all assets [S1].
• The company was in discussions with its lender regarding potential extension of credit facilities but noted no assurance of extension or terms [S1].
• AMS faces customer concentration risk, with two customers accounting for approximately 26% and 31% of revenue in 2025 [S1].
• The company’s radiosurgery devices have been purchased exclusively from Elekta to date, though other manufacturers exist [S1].
• AMS’s internal control over financial reporting had a material weakness as of December 31, 2025, which could affect timely and accurate financial reporting [S1].
• Recent news reports highlight strong revenue growth, including 17% year-over-year revenue growth for Q1 2025 and expansion plans [N1][N3].
• The company held earnings conference calls and reported quarterly earnings in 2025 [N2][N4].